U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07836452) titled 'A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants' on Sept. 16.
Brief Summary: This is a first-in-human (FIH), multicenter, randomized, double-masked, placebo-controlled adaptive clinical study evaluating the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of CITY-RBP4, following single-ascending doses and multiple doses, via subcutaneous (SC) administration.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Stargardt Disease 1
STGD1
Healthy Volunteers
Intervention:
DRUG: CITY-RBP4
siRNA (subcutaneous injection)
DRUG: Placebo
Saline (subcutaneou...